Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Bladder Cancer; Small-cell Lung Cancer; Prostate Cancer; Thyroid Cancer; Sarcoma; Gastric Cancer; Gallbladder Cancer

Interventions: Drug: TT-00420; Combination Product: Nab-Paclitaxel

Sponsors: TransThera Sciences (Nanjing), Inc.

Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 4, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments